Clinical Trials Directory

Trials / Completed

CompletedNCT04590976

Metastatic Prostate Cancer Men's Attitudes Towards Treatment of the Local Tumour and Metastasis Evaluative Research

Patients' Preferences in the Treatment of Hormone-sensitive Metastatic Prostate Cancer: a Discrete Choice Experiment

Status
Completed
Phase
Study type
Observational
Enrollment
320 (actual)
Sponsor
Imperial College London · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

Systemic therapy (i.e Androgen Deprivation Therapy with Docetaxel, Enzalutamide, Apalutamide or Abiraterone Acetate) has increased overall survival in men with hormone-sensitive metastatic prostate cancer. Novel local cytoreductive treatments and metastasis directed therapy are being evaluated, these can confer additional harm, but might improve survival. We aim to elicit men's preferences for and willingness to accept trade-offs between potential improved survival and cytoreductive treatment risks using a 'discrete choice experiment'.

Detailed description

OBJECTIVES: To determine the attributes associated with treatment that are most important to men with hormone-sensitive metastatic prostate cancer (mPCa). To determine men's preferences for, and trade-offs between, the attributes (survival and side-effects) of different treatment options in metastatic prostate cancer including systemic therapy, local and metastases-directed physical therapies. PHASE: Prospective multi-centre observational cohort DESIGN: Discrete choice experiment, single-visit, electronic questionnaire design SAMPLE SIZE: Multi-centre Stage (Stage 3) n = 300 patients POPULATION: Men with newly-diagnosed metastatic prostate cancer who have not consented to a form of local cytoreductive or metastasis directed therapy.

Conditions

Interventions

TypeNameDescription
OTHERSemi-Structured Interview Healthcare ProfessionalInterview
OTHERSemi-Structured Interview PatientsInterview
OTHERThink Aloud Interview PatientsInterview
OTHERDiscrete Choice Experiment (DCE) PatientsDCE Questionnaire

Timeline

Start date
2020-12-03
Primary completion
2023-02-01
Completion
2023-02-01
First posted
2020-10-19
Last updated
2023-02-08

Locations

35 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04590976. Inclusion in this directory is not an endorsement.